- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Advances in Pharmacological Sciences
Volume 2012 (2012), Article ID 134523, 10 pages
An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists
1Phase I Unit of Clinical Pharmacological Research Center, Peking Union Medical College Hospital, 100032 Beijing, China
2Centre for Human Drug Research, 2333 CL Leiden, The Netherlands
Received 9 July 2011; Revised 2 December 2011; Accepted 7 December 2011
Academic Editor: Keith Wafford
Copyright © 2012 Xia Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- M. E. P. Seligman, E. F. Walker, and D. L. Rosenhan, Abnormal Psychology, W.W. Norton & Company, New York, NY, USA, 4th edition, 2000.
- A. S. Eison and U. L. Mullins, “Regulation of central 5- receptors: a review of in vivo studies,” Behavioural Brain Research, vol. 73, no. 1-2, pp. 177–181, 1995.
- G. Wong and P. Skolnick, “High affinity ligands for “diazepam-insensitive” benzodiazepines receptors,” European Journal of Pharmacology—Molecular Pharmacology Section, vol. 225, no. 1, pp. 63–68, 1992.
- J. R. Atack, “Subtype-selective receptor modulation yields a novel pharmacological profile: the design and development of TPA023,” Advances in Pharmacology, vol. 57, pp. 137–185, 2009.
- R. M. McKernan, T. W. Rosahl, D. S. Reynolds et al., “Sedative but not anxiolytic properties of benzodiazepines are mediated by the receptor α1 subtype,” Nature Neuroscience, vol. 3, no. 6, pp. 587–592, 2000.
- J. K. Rowlett, D. M. Platt, S. Lelas, J. R. Atack, and G. R. Dawson, “Different receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 3, pp. 915–920, 2005.
- J. Knabl, R. Witschi, K. Hösl et al., “Reversal of pathological pain through specific spinal receptor subtypes,” Nature, vol. 451, no. 7176, pp. 330–334, 2008.
- J. Knabl, U. B. Zeilhofer, F. Crestani, U. Rudolph, and H. U. Zeilhofer, “Genuine antihyperalgesia by systemic diazepam revealed by experiments in receptor point-mutated mice,” Pain, vol. 141, no. 3, pp. 233–238, 2009.
- J. R. Atack, P. J. Bayley, G. R. Seabrook, K. A. Wafford, R. M. McKernan, and G. R. Dawson, “L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for α5-containing receptors,” Neuropharmacology, vol. 51, no. 6, pp. 1023–1029, 2006.
- T. M. Ballard, F. Knoflach, E. Prinssen et al., “RO4938581, a novel cognitive enhancer acting at GABAA α5 subunit-containing receptors,” Psychopharmacology, vol. 202, no. 1–3, pp. 207–223, 2009.
- S. J. De Visser, J. P. Van Der Post, P. P. De Waal, F. Cornet, A. F. Cohen, and J. M. A. Van Gerven, “Biomarkers for the effects of benzodiazepines in healthy volunteers,” British Journal of Clinical Pharmacology, vol. 55, no. 1, pp. 39–50, 2003.
- S. L. De Haas, S. J. De Visser, J. P. Van Der Post et al., “Pharmacodynamic and pharmacokinetic effects of TPA023, a α2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers,” Journal of Psychopharmacology, vol. 21, no. 4, pp. 374–383, 2007.
- S. L. De Haas, S. J. De Visser, J. P. Van Der Post et al., “Pharmacodynamic and pharmacokinetic effects of MK-0343, a α2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers,” Journal of Psychopharmacology, vol. 22, no. 1, pp. 24–32, 2008.
- S. L. De Haas, K. L. Franson, J. A. J. Schmitt et al., “The pharmacokinetic and pharmacodynamic effects of SL65.1498, a 2,3 selective agonist, in comparison with lorazepam in healthy volunteers,” Journal of Psychopharmacology, vol. 23, no. 6, pp. 625–632, 2009.
- S. L. De Haas, R. C. Schoemaker, J. M. A. Van Gerven, P. Hoever, A. F. Cohen, and J. Dingemanse, “Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects,” Journal of Psychopharmacology, vol. 24, no. 11, pp. 1619–1629, 2010.
- A. L. Van Steveninck, B. N. M. Van Berckel, R. C. Schoemaker, D. D. Breimer, J. M. A. Van Gerven, and A. F. Cohen, “The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation,” Journal of Psychopharmacology, vol. 13, no. 1, pp. 10–17, 1999.
- J. M. P. Baas, N. Mol, J. L. Kenemans et al., “Validating a human model for anxiety using startle potentiated by cue and context: the effects of alprazolam, pregabalin, and diphenhydramine,” Psychopharmacology, vol. 205, no. 1, pp. 73–84, 2009.
- A. L. Van Steveninck, S. Verver, H. C. Schoemaker et al., “Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual volunteers,” Clinical Pharmacology and Therapeutics, vol. 52, no. 4, pp. 402–408, 1992.
- A. L. Van Steveninck, H. C. Schoemaker, M. S. M. Pieters, R. Kroon, D. D. Breimer, and A. F. Cohen, “A comparison of the sensitivities of adaptive tracking, eye movement analysis, and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers,” Clinical Pharmacology and Therapeutics, vol. 50, no. 2, pp. 172–180, 1991.
- P. R. M. Bittencourt, P. Wade, A. T. Smith, and A. Richens, “The relationship between peak velocity of saccadic eye movements and serum benzodiazepine concentration,” British Journal of Clinical Pharmacology, vol. 12, no. 4, pp. 523–533, 1981.
- R. W. Baloh, A. W. Sills, W. E. Kumley, and V. Honrubia, “Quantitative measurement of saccade amplitude duration, and velocity,” Neurology, vol. 25, no. 11, pp. 1065–1070, 1975.
- H. Norris, “The action of sedatives on brain stem oculomotor systems in man,” Neuropharmacology, vol. 10, no. 2, pp. 181–191, 1971.
- A. Bond and M. Lader, “The use of analogue scales in rating subjective feelings,” British Journal of Medical Psychology, vol. 47, pp. 211–218, 1974.
- A. L. Van Steveninck, R. Gieschke, H. C. Schoemaker et al., “Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state,” Psychopharmacology, vol. 110, no. 4, pp. 471–478, 1993.
- A. L. Van Steveninck, A. E. Wallnöfer, R. C. Schoemaker et al., “A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population,” British Journal of Clinical Pharmacology, vol. 44, no. 3, pp. 267–275, 1997.
- J. R. Atack, K. A. Wafford, S. J. Tye et al., “TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3- (2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for α2- and 3-containing receptors, is a nonsedating anxiolytic in rodents and primates,” Journal of Pharmacology and Experimental Therapeutics, vol. 316, no. 1, pp. 410–422, 2006.
- R. G. Borland and A. N. Nicholson, “Visual motor co-ordination and dynamic visual acuity,” British Journal of Clinical Pharmacology, vol. 18, no. 1, pp. 69S–72S, 1984.
- G. Griebel, G. Perrault, J. Simiand et al., “SL651498: an anxioselective compound with functional selectivity for α2- and α3-containing γ-aminobutyric () receptors,” Journal of Pharmacology and Experimental Therapeutics, vol. 298, no. 2, pp. 753–768, 2001.
- F. Crestani, J. R. Martin, H. Möhler, and U. Rudolph, “Mechanism of action of the hypnotic zolpidem in vivo,” British Journal of Pharmacology, vol. 131, no. 7, pp. 1251–1254, 2000.
- E. Sanna, F. Busonero, G. Talani et al., “Comparison of the effects of zaleplon, zolpidem, and triazolam at various receptor subtypes,” European Journal of Pharmacology, vol. 451, no. 2, pp. 103–110, 2002.